Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821

C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a s...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology Immunotherapy 1982-01, Vol.14 (1), p.59-60
Main Authors: Lang, J M, Giron, C, Aleksijevic, A, Marchiani, C, Zalisz, R, Oberling, F
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Aged
Female
Glycoproteins - administration & dosage
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Humans
Hypersensitivity, Delayed - immunology
Klebsiella pneumoniae
Lymphoma - drug therapy
Lymphoma - immunology
Male
Middle Aged
Neoplasms - drug therapy
Neoplasms - immunology
Short Communication
Skin Tests
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c369t-9ccdd15c7e75eb9233555b78641860c45944b28a27762fe7f07463c01575198a3
cites
container_end_page 60
container_issue 1
container_start_page 59
container_title Cancer Immunology Immunotherapy
container_volume 14
creator Lang, J M
Giron, C
Aleksijevic, A
Marchiani, C
Zalisz, R
Oberling, F
description C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significantly (P less than 0.02) enhanced skin reactions, as shown using the Multitest system.
doi_str_mv 10.1007/BF00199434
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11039261</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>13645215</sourcerecordid><originalsourceid>FETCH-LOGICAL-c369t-9ccdd15c7e75eb9233555b78641860c45944b28a27762fe7f07463c01575198a3</originalsourceid><addsrcrecordid>eNpVkcuLFDEQxoMo67h68S7k5GGhNZVn5yQ67ENY8LJ7Dpl09XakH2OSHhnYP96enWHVUxXUr776qI-Q98A-AWPm87crxsBaKeQLsgIpeMVqBS_JignJKsOYfE3e5PxzaTiz9oycacuV1LAij5dj58eAA46FTi1tsPd7bGiYix9xmjPt9ltMGcccS9zFsqdxpPNYEvpy4A7LiW59iYtCpg9xhyP1NHdTKlXBNNAp-Z4-8U9HfsfS0TWFmsNb8qr1fcZ3p3pO7q8u79Y31e2P6-_rr7dVENqWyobQNKCCQaNwY7kQSqmNqbWEWrMglZVyw2vPjdG8RdMyI7UIDJRRYGsvzsmXo-523gzYhMXG4sltUxx82rvJR_f_ZIyde5h2DoAJyzUsCh9PCmn6NWMubog5YN8fn-RAaKk4qAW8OIIhTTknbJ-vAHOHsNzfsBb4w7--ntFTOuIP2WeQdA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>13645215</pqid></control><display><type>article</type><title>Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821</title><source>PubMed Central Free</source><source>Springer Nature - Connect here FIRST to enable access</source><creator>Lang, J M ; Giron, C ; Aleksijevic, A ; Marchiani, C ; Zalisz, R ; Oberling, F</creator><creatorcontrib>Lang, J M ; Giron, C ; Aleksijevic, A ; Marchiani, C ; Zalisz, R ; Oberling, F</creatorcontrib><description>C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significantly (P less than 0.02) enhanced skin reactions, as shown using the Multitest system.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/BF00199434</identifier><identifier>PMID: 6925461</identifier><language>eng</language><publisher>Germany: Springer-Verlag</publisher><subject>Administration, Oral ; Adult ; Aged ; Female ; Glycoproteins - administration &amp; dosage ; Hodgkin Disease - drug therapy ; Hodgkin Disease - immunology ; Humans ; Hypersensitivity, Delayed - immunology ; Klebsiella pneumoniae ; Lymphoma - drug therapy ; Lymphoma - immunology ; Male ; Middle Aged ; Neoplasms - drug therapy ; Neoplasms - immunology ; Short Communication ; Skin Tests</subject><ispartof>Cancer Immunology Immunotherapy, 1982-01, Vol.14 (1), p.59-60</ispartof><rights>Springer-Verlag 1982</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c369t-9ccdd15c7e75eb9233555b78641860c45944b28a27762fe7f07463c01575198a3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039261/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11039261/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6925461$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, J M</creatorcontrib><creatorcontrib>Giron, C</creatorcontrib><creatorcontrib>Aleksijevic, A</creatorcontrib><creatorcontrib>Marchiani, C</creatorcontrib><creatorcontrib>Zalisz, R</creatorcontrib><creatorcontrib>Oberling, F</creatorcontrib><title>Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821</title><title>Cancer Immunology Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><description>C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significantly (P less than 0.02) enhanced skin reactions, as shown using the Multitest system.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Glycoproteins - administration &amp; dosage</subject><subject>Hodgkin Disease - drug therapy</subject><subject>Hodgkin Disease - immunology</subject><subject>Humans</subject><subject>Hypersensitivity, Delayed - immunology</subject><subject>Klebsiella pneumoniae</subject><subject>Lymphoma - drug therapy</subject><subject>Lymphoma - immunology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - immunology</subject><subject>Short Communication</subject><subject>Skin Tests</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1982</creationdate><recordtype>article</recordtype><recordid>eNpVkcuLFDEQxoMo67h68S7k5GGhNZVn5yQ67ENY8LJ7Dpl09XakH2OSHhnYP96enWHVUxXUr776qI-Q98A-AWPm87crxsBaKeQLsgIpeMVqBS_JignJKsOYfE3e5PxzaTiz9oycacuV1LAij5dj58eAA46FTi1tsPd7bGiYix9xmjPt9ltMGcccS9zFsqdxpPNYEvpy4A7LiW59iYtCpg9xhyP1NHdTKlXBNNAp-Z4-8U9HfsfS0TWFmsNb8qr1fcZ3p3pO7q8u79Y31e2P6-_rr7dVENqWyobQNKCCQaNwY7kQSqmNqbWEWrMglZVyw2vPjdG8RdMyI7UIDJRRYGsvzsmXo-523gzYhMXG4sltUxx82rvJR_f_ZIyde5h2DoAJyzUsCh9PCmn6NWMubog5YN8fn-RAaKk4qAW8OIIhTTknbJ-vAHOHsNzfsBb4w7--ntFTOuIP2WeQdA</recordid><startdate>19820101</startdate><enddate>19820101</enddate><creator>Lang, J M</creator><creator>Giron, C</creator><creator>Aleksijevic, A</creator><creator>Marchiani, C</creator><creator>Zalisz, R</creator><creator>Oberling, F</creator><general>Springer-Verlag</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>19820101</creationdate><title>Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821</title><author>Lang, J M ; Giron, C ; Aleksijevic, A ; Marchiani, C ; Zalisz, R ; Oberling, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c369t-9ccdd15c7e75eb9233555b78641860c45944b28a27762fe7f07463c01575198a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1982</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Glycoproteins - administration &amp; dosage</topic><topic>Hodgkin Disease - drug therapy</topic><topic>Hodgkin Disease - immunology</topic><topic>Humans</topic><topic>Hypersensitivity, Delayed - immunology</topic><topic>Klebsiella pneumoniae</topic><topic>Lymphoma - drug therapy</topic><topic>Lymphoma - immunology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - immunology</topic><topic>Short Communication</topic><topic>Skin Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, J M</creatorcontrib><creatorcontrib>Giron, C</creatorcontrib><creatorcontrib>Aleksijevic, A</creatorcontrib><creatorcontrib>Marchiani, C</creatorcontrib><creatorcontrib>Zalisz, R</creatorcontrib><creatorcontrib>Oberling, F</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, J M</au><au>Giron, C</au><au>Aleksijevic, A</au><au>Marchiani, C</au><au>Zalisz, R</au><au>Oberling, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821</atitle><jtitle>Cancer Immunology Immunotherapy</jtitle><addtitle>Cancer Immunol Immunother</addtitle><date>1982-01-01</date><risdate>1982</risdate><volume>14</volume><issue>1</issue><spage>59</spage><epage>60</epage><pages>59-60</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>C 1821 is a purified glycoprotein extract of Klebsiella pneumoniae serotype 2 with immunomodulating properties in animals (in vivo and in vitro) and in humans (in vitro). The compound is devoid of any apparent toxicity when given orally. The aim of the present work was to evaluate the effects of a short term oral administration of C 1821 on delayed cutaneous hypersensitivity to recall antigens in untreated cancer patients (mostly lymphomas). Consecutive patients were alternately allocated to receive C 1821 or placebo for 14 days. C 1821 restored and significantly (P less than 0.02) enhanced skin reactions, as shown using the Multitest system.</abstract><cop>Germany</cop><pub>Springer-Verlag</pub><pmid>6925461</pmid><doi>10.1007/BF00199434</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0340-7004
ispartof Cancer Immunology Immunotherapy, 1982-01, Vol.14 (1), p.59-60
issn 0340-7004
1432-0851
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11039261
source PubMed Central Free; Springer Nature - Connect here FIRST to enable access
subjects Administration, Oral
Adult
Aged
Female
Glycoproteins - administration & dosage
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Humans
Hypersensitivity, Delayed - immunology
Klebsiella pneumoniae
Lymphoma - drug therapy
Lymphoma - immunology
Male
Middle Aged
Neoplasms - drug therapy
Neoplasms - immunology
Short Communication
Skin Tests
title Enhancement of delayed cutaneous hypersensitivity in untreated cancer patients given a short-term oral treatment with C 1821
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T20%3A01%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancement%20of%20delayed%20cutaneous%20hypersensitivity%20in%20untreated%20cancer%20patients%20given%20a%20short-term%20oral%20treatment%20with%20C%201821&rft.jtitle=Cancer%20Immunology%20Immunotherapy&rft.au=Lang,%20J%20M&rft.date=1982-01-01&rft.volume=14&rft.issue=1&rft.spage=59&rft.epage=60&rft.pages=59-60&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/BF00199434&rft_dat=%3Cproquest_pubme%3E13645215%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c369t-9ccdd15c7e75eb9233555b78641860c45944b28a27762fe7f07463c01575198a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=13645215&rft_id=info:pmid/6925461&rfr_iscdi=true